---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-011569"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:34:35.925340+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics refutes Culper Research short seller allegations; provides inventory & demand data

## Summary
- Demand for ASCENIV growing; end-user demand increased past two years; current days on hand average 90 days as of March 22, 2026.
- Refutes channel stuffing; says distributor inventory levels consistent with industry standards; average days on hand above safety stock: 48 days for ASCENIV, 51 days for BIVIGAM as of March 22.
- ASCENIV positioned as late-line therapy for immune compromised patients who fail standard IG; premium pricing; new IVIG launches not competitive threat.
- ADMA received unqualified audit opinions from Big Four firm for FY2024 and FY2025; prior auditor resigned due to acquisition.
- No undisclosed related party transactions; no Grossman-family entity distributed or took title to any ADMA products.

## SEC filing metadata
- accession: 0001140361-26-011569
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036126011569/0001140361-26-011569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036126011569/ef20069109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-011569
- JSON: https://secwatch.observer/filing/0001140361-26-011569.json
- Plain text: https://secwatch.observer/filing/0001140361-26-011569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.